MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571390 | Name: Libenzapril

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Libenzapril is an angiotensin-converting enzyme inhibitor.

Chemical Structure

Libenzapril
Libenzapril
CAS#109214-55-3

Theoretical Analysis

MedKoo Cat#: 571390

Name: Libenzapril

CAS#: 109214-55-3

Chemical Formula: C18H25N3O5

Exact Mass: 363.1794

Molecular Weight: 363.41

Elemental Analysis: C, 59.49; H, 6.93; N, 11.56; O, 22.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Libenzapril; Abutapril; CGS 16617.
IUPAC/Chemical Name
1H-1-Benzazepine-1-acetic acid, 3-((5-amino-1-carboxypentyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,R*))
InChi Key
AXTCRUUITQKBAV-KBPBESRZSA-N
InChi Code
InChI=1S/C18H25N3O5/c19-10-4-3-6-14(18(25)26)20-13-9-8-12-5-1-2-7-15(12)21(17(13)24)11-16(22)23/h1-2,5,7,13-14,20H,3-4,6,8-11,19H2,(H,22,23)(H,25,26)/t13-,14-/m0/s1
SMILES Code
O=C(O)CN1C([C@@H](N[C@H](C(O)=O)CCCCN)CCC2=CC=CC=C21)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 363.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tang JP, Rakhit A, Douglas FL, Melethil S. Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril. Pharm Res. 1992 Feb;9(2):236-43. PubMed PMID: 1553348. 2: Morgan JM, Piraino AJ, Saris SD, Graham CS, Hirschhorn WL, Kochak GM, Choi RL. Inhibition of angiotensin-converting enzyme with libenzapril in normotensive males. J Clin Pharmacol. 1994 Dec;34(12):1177-82. PubMed PMID: 7738213. 3: Kochak GM, Choi RL, deSilva JK, Reydel-Bax P. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril. J Clin Pharmacol. 1990 Feb;30(2):138-43. PubMed PMID: 2312764. 4: Tang JP, Xu ZQ, Douglas FL, Rakhit A, Melethil S. Increased blood-brain barrier permeability of amino acids in chronic hypertension. Life Sci. 1993;53(25):PL417-20. PubMed PMID: 7902950. 5: Levens NR, Cóte D, Ksander G. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism. J Pharmacol Exp Ther. 1991 Oct;259(1):219-27. PubMed PMID: 1920118. 6: Molteni A, Ward WF, Ts'ao C, Solliday NH. Monocrotaline-induced cardiopulmonary injury in rats: modification by the nonthiol ACE inhibitors CGS13945 and CGS16617. Arch Int Pharmacodyn Ther. 1988 Jan-Feb;291:21-40. PubMed PMID: 3129998. 7: Kochak GM, Smith RA, Choi RL, John V, Tipnis V, Honc F, deSilva JK, Weidler DJ. Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617. Pharm Res. 1989 Apr;6(4):328-31. PubMed PMID: 2748520. 8: Gaudry D, Hayes M, Khemani L, Miotto J, Alkalay D. Determination of CGS 16617 and stable isotope-labeled CGS 16617, an angiotensin-converting enzyme inhibitor, in human plasma by gas chromatography/mass spectrometry. Biol Mass Spectrom. 1991 Jan;20(1):26-30. PubMed PMID: 1883857. 9: Choi RL, Kochak GM, Reydel-Bax P, Nelson EB. Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects. J Clin Pharmacol. 1988 Sep;28(9):848-52. PubMed PMID: 3230152. 10: Levens NR, Ksander GM, Zimmerman MB, Mullane KM. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors. Hypertension. 1989 Jan;13(1):51-62. PubMed PMID: 2910814. 11: Smith EF 3rd, Egan JW, Goodman FR, Zimmerman MB, Webb RL, Ribeiro LG. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat. Pharmacology. 1988;37(4):254-63. PubMed PMID: 2973611. 12: Reydel-Bax P, Redalieu E, Rakhit A. Direct determination of angiotensin-converting enzyme inhibitors in plasma by radioenzymatic assay. Clin Chem. 1987 Apr;33(4):549-53. PubMed PMID: 3030582. 13: Kim JS, Oberle RL, Krummel DA, Dressman JB, Fleisher D. Absorption of ACE inhibitors from small intestine and colon. J Pharm Sci. 1994 Sep;83(9):1350-6. PubMed PMID: 7830254. 14: Bitterman H, Phillips GR 3rd, Dragon G, Lefer AM. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock. J Pharmacol Exp Ther. 1987 Jul;242(1):8-14. PubMed PMID: 3039116. 15: Weiss GB, Sturm B, Levens NR. Rapid reversal of angiotensin I-induced contractions in rat carotid arteries after acute and chronic treatment with the angiotensin-converting enzyme inhibitor, 3-[(5-amino-1-carboxy-1S-pentyl)amino]2,3,4,5-tetrahydro-2-oxo- 3S-1H-1-benzazepena-1-acetic acid (CGS 16617). J Pharmacol Exp Ther. 1993 Dec;267(3):1407-13. PubMed PMID: 8263802. 16: Waeber G, Burnier M, Porchet M, Nussberger J, Waeber B, Brunner HR. Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers. Eur J Clin Pharmacol. 1989;36(6):587-91. PubMed PMID: 2550244. 17: Grupp LA, Chow SY. Time-dependent effect of the angiotensin converting enzyme inhibitor, abutapril, on voluntary alcohol intake in the rat. Alcohol Alcohol. 1992 May;27(3):267-71. PubMed PMID: 1449562. 18: Tsuji Y, Goldfarb DA, Masaki Z, Ferrario CM. Patterns of renal function in hypertension due to unilateral renal artery occlusion. Clin Exp Hypertens A. 1992;14(6):1067-81. PubMed PMID: 1358485. 19: Bitterman H, Lefer DJ, Lefer AM. Additive beneficial effects of two inhibitors of vasoconstrictor mediators in acute myocardial ischemia. Proc Soc Exp Biol Med. 1987 Jul;185(3):262-6. PubMed PMID: 3037554. 20: Levens NR. Renal actions of the new angiotensin converting enzyme inhibitor CGS 16617. Arch Int Pharmacodyn Ther. 1988 Mar-Apr;292:266-80. PubMed PMID: 2840040.